公开(公告)号：US08703491B2

公开(公告)日：2014-04-22

申请号：US13679977

申请日：2012-11-16

申请人： Vivia Biotech S.L.

发明人： Alex Okun

IPC分类号： G01N21/05 ,  G01N1/10 ,  G01N35/10

CPC分类号： G01N35/1095 ,  G01N35/1009 ,  G01N35/1065 ,  G01N35/1097 ,  Y10T436/11 ,  Y10T436/117497 ,  Y10T436/118339 ,  Y10T436/119163 ,  Y10T436/2575

摘要： Disclosed herein is a sample supply device that alternates between the supply of samples from one sample line while cleaning a second sample line and then supplying a second sample from the second sample line while cleaning the first sample line. This is repeated in rapid succession to allow greater speed in analyzing a plurality of samples in a shorter amount of time.

摘要翻译： 本文公开了一种样品供应装置，其在清洁第二样品管线之间从一个样品管线供应的样品之间交替，然后在清洁第一样品管线的同时从第二样品管线提供第二样品。 快速连续重复这一步骤，以便在更短的时间内分析多个样品的速度更快。

公开(公告)号：US20130109101A1

公开(公告)日：2013-05-02

申请号：US13679977

申请日：2012-11-16

申请人： VIVIA BIOTECH S.L

发明人： Alex Okun

IPC分类号： G01N35/10

CPC分类号： G01N35/1095 ,  G01N35/1009 ,  G01N35/1065 ,  G01N35/1097 ,  Y10T436/11 ,  Y10T436/117497 ,  Y10T436/118339 ,  Y10T436/119163 ,  Y10T436/2575

摘要： Disclosed herein is a sample supply device that alternates between the supply of samples from one sample line while cleaning a second sample line and then supplying a second sample from the second sample line while cleaning the first sample line. This is repeated in rapid succession to allow greater speed in analyzing a plurality of samples in a shorter amount of time.

摘要翻译： 本文公开了一种样品供应装置，其在清洁第二样品管线之间从一个样品管线供应的样品之间交替，然后在清洁第一样品管线的同时从第二样品管线提供第二样品。 快速连续重复这一步骤，以便在更短的时间内分析多个样品的速度更快。

公开(公告)号：US20210189336A1

公开(公告)日：2021-06-24

申请号：US16757522

申请日：2018-10-18

申请人： VIVIA BIOTECH, S.L.

发明人： Daniel PRIMO RAMOS ,  Juan Antonio BALLESTEROS NOBELL ,  Teresa Ann BENNETT ,  Julián GORROCHATEGUI GUILLÉN ,  Joaquín MARTÍNEZ LÓPEZ ,  Antonio VALERI LOZANO ,  Alejandra LEIVAS ALDEA

IPC分类号： C12N5/0783 ,  G01N33/50 ,  A61K35/17 ,  A61K45/06 ,  A61K39/395 ,  A61P35/00

摘要： The CAR-T cells described herein can provide highly effective therapies for diverse cancer types, e.g., solid cancers, hematological cancers, and metastatic forms thereof.
Provided herein are methods of generating CAR-T cells, compositions comprising such CAR-T cells, methods of treatment using the cells, methods of identifying subjects susceptible to immune checkpoint immunotherapy treatment and methods of evaluating susceptibility of a subject to develop Cytokine-Release Syndrome.

公开(公告)号：US20190212325A1

公开(公告)日：2019-07-11

申请号：US15773400

申请日：2016-11-04

申请人： VIVIA BIOTECH, S.L

发明人： Juan Antonio BALLESTEROS NOBELL ,  Teresa BENNETT ,  Daniel PRIMO RAMOS ,  Paolo PROSPERO GHIA ,  Ana Belén ESPINOSA OQUILLAS ,  Julián GORROCHATEGUI GUILLÉN ,  Alicia ROBLES MATEOS ,  Pilar HERNÁNDEZ CAMPO

IPC分类号： G01N33/50 ,  C12N5/09

CPC分类号： G01N33/5011 ,  C12N5/0694 ,  C12N2500/40 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2313 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2502/30 ,  C12N2503/02 ,  C12N2513/00 ,  G01N33/5044 ,  G01N33/5088

摘要： The invention presented here relates to a method for producing an artificial environment of primary cell populations, particularly an artificial tumor environment of primary tumor cell populations and its use in an ex vivo method to test the cellular responsiveness of primary tumor cell populations to a drug or drugs. The method of the invention comprises incubation of the primary tumor cells with the artificial tumor environment and the drug or drugs and analyze the response of the primary tumor cell populations. The incubation of the primary tumor cells with the artificial tumor environment, enhances the viability of said tumor cells and/or induces greater levels of tumor cell proliferation and, consequently, increases the sensitivity and accuracy of the test with regard to the drug/s assayed.

公开(公告)号：US20170205395A1

公开(公告)日：2017-07-20

申请号：US15460872

申请日：2017-03-16

申请人： VIVIA BIOTECH, S.L.

发明人： Juan Ballesteros ,  Teresa Bennett ,  Daniel Primo ,  Alberto Orfao ,  Coyt Jackson ,  Santiago Lago ,  Maria Matoses ,  Lilia Suarez ,  Sandra Sapia ,  Andrew Bosanquet ,  Julian Corrochategui ,  Consuelo Tudela ,  Pilar Hernandez ,  Luis Ignacio Caveda

IPC分类号： G01N33/50

CPC分类号： G01N33/5011 ,  G01N33/57407 ,  G01N33/57426 ,  G01N2800/52

摘要： Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.

公开(公告)号：US20190218515A1

公开(公告)日：2019-07-18

申请号：US16093867

申请日：2017-04-12

申请人： VIVIA BIOTECH, S.L.

发明人： Juan Antonio BALLESTEROS NOBELL ,  Teresa Ann BENNET ,  Pilar HERNÁNDEZ CAMPO ,  Cristina GÓMEZ GONZÁLEZ ,  Julián GORROCHATEGUI GUILLÉN ,  Joaquín MARTÍNEZ LÓPEZ ,  Alicia ROBLES MATEOS ,  Daniel PRIMOS RAMOS

IPC分类号： C12N5/0783 ,  A61P35/02 ,  A61K45/00

CPC分类号： C12N5/0638 ,  A61K39/0011 ,  A61K45/05 ,  A61K2039/5158 ,  A61K2039/572 ,  A61P35/02

摘要： Generation and identification of highly effective immune effector cell in terms of target cell-killing activity can be enhanced by optimizing the proximity between a target cell and the immune effector cell. The cancer-killing T cells described herein can provide highly effective therapies for diverse cancer types, e.g., solid cancers, hematological cancers, and metastatic forms thereof. Provided herein are ex-vivo methods of generating cancer-killing T cells, compositions comprising such immune cells; methods of using the cells, methods of selecting optimal agents for enhancing the target cell killing activity, methods of selecting an optimized immune cell and methods of using this approach to evaluate patient responsiveness to other cancer therapies.